再拓海外新局 翰森制药授予Glenmark阿美替尼多区域独家权益

Core Viewpoint - Hansoh Pharmaceutical Group Co., Ltd. has entered into an exclusive licensing, collaboration, and distribution agreement with Glenmark Specialty S.A. for Amivantamab, a third-generation EGFR-TKI for non-small cell lung cancer (NSCLC) [1] Group 1: Agreement Details - The agreement grants Glenmark exclusive rights to develop and commercialize Amivantamab in specified regions including the Middle East, Africa, Southeast Asia, South Asia, Australia, New Zealand, Russia, and certain Caribbean countries [1] - Hansoh Pharmaceutical will receive an upfront payment along with potential milestone payments exceeding $1 billion, as well as tiered royalties on net sales within the licensed regions [1]